ArticleArchives of microbiology2026
Integrative in vitro and in silico assessment of bicyclic monoterpenes as antifungal agents targeting the cell membrane integrity of Candida albicans.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The yeast Candida is a common component of the human microbiota. An imbalance in the colonization of this commensal form can lead to an infection that presents symptoms ranging from mild localized rashes to severe disseminated disease. The primary treatment for candidiasis typically includes antifungal drugs belonging to the class of azoles that target cell membranes. Given the substantial rise in resistance to antifungal medications in recent years, it is imperative to explore novel therapeutic options for managing candidiasis, which has emerged as a significant medical challenge. Plant-derived compounds possessing antifungal properties, particularly monoterpenes, have been recognized as promising alternatives. However, while acyclic and monocyclic monoterpenes have been extensively investigated, bicyclic monoterpenes have not received adequate attention. Our aim was to assess the antifungal potential of nopol and myrtenol, two bicyclic monoterpenes, against Candida albicans. Broth microdilution assays demonstrated the inhibition of fungal growth, with minimum inhibitory concentration (MIC) values of 878 and 1681 µM, respectively. The compounds were examined for their impact on membrane integrity by estimation of ergosterol content, scanning electron microscopy, fluorescence microscopy, propidium iodide (PI) uptake, and H
Indexed as
Identifiers
41944880What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.